Table 3. Apparent prevalences with 95% confidence interval per locality, sampling phase and test: IFAT = indirect immunofluorescence test; DAT = direct agglutination test; PAR = parallel interpretation of the two test results; SER = serial interpretation of the two test results.

		First round	Second round
Tlemcen	IFAT	0.35 (0.28–0.42)	0.37 (0.28–0.46)
	DAT	0.15 (0.10–0.21)	0.24 (0.16–0.32)
	PAR	0.41 (0.34–0.49)	0.47 (0.38–0.56)
	SER	0.09 (0.05–0.14)	0.13 (0.08–0.20)
Mostaganem	IFAT	0.43 (0.35–0.52)	0.27 (0.21–0.35)
	DAT	0.08 (0.04–0.14)	0.13 (0.08–0.19)
	PAR	0.43 (0.35–0.52)	0.29 (0.22–0.36)
	SER	0.08 (0.04–0.14)	0.11 (0.07–0.17)
Tipaza	IFAT	0.34 (0.28–0.40)	0.32 (0.26–0.39)
	DAT	0.31 (0.25–0.37)	0.33 (0.27–0.40)
	PAR	0.54 (0.47–0.61)	0.41 (0.34–0.48)
	SER	0.11 (0.07–0.15)	0.24 (0.18–0.30)
Boumerdes	IFAT	0.34 (0.28–0.41)	0.38 (0.29–0.48)
	DAT	0.18 (0.13–0.24)	0.29 (0.21–0.39)
	PAR	0.45 (0.38–0.52)	0.45 (0.35–0.55)
	SER	0.08 (0.05–0.13)	0.22 (0.15–0.32)
Bejaia	IFAT	0.47 (0.40–0.55)	0.47 (0.40–0.54)
	DAT	0.29 (0.23–0.36)	0.36 (0.30–0.43)
	PAR	0.62 (0.54–0.68)	0.52 (0.45–0.59)
	SER	0.15 (0.10–0.21)	0.31 (0.25–0.38)
Jijel	IFAT	0.30 (0.24–0.36)	0.37 (0.30–0.45)
	DAT	0.29 (0.23–0.35)	0.29 (0.22–0.36)
	PAR	0.44 (0.37–0.51)	0.41 (0.34–0.49)
	SER	0.14 (0.10–0.20)	0.24 (0.18–0.31)